S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying the chromosomes in samples of bone marrow and blood in the laboratory from patients with cancer or other blood diseases may help doctors learn more about the disease. PURPOSE: This laboratory study is analyzing chromosomes in patients with newly diagnosed multiple myeloma or other blood disease.

Detailed Description
-----------------
OBJECTIVES: Compare the frequency of deletion 13 as detected by fluorescence in situ hybridization (FISH) and conventional cytogenetics in patients with newly diagnosed multiple myeloma (MM) or other monoclonal gammopathies (MG). Examine the prognostic value of specific subsets of chromosome aberrations detected by conventional cytogenetics and FISH in relation to event-free and overall survival in these patients. Compare the prognostic value of cytogenetics and FISH with other MM and MG prognostic factors in these patients. Correlate the presence of cytogenetic and FISH features with clinical pathophysiological, cellular, or other molecular characteristics in these patients. OUTLINE: Patients receive treatment as directed by the treatment clinical trial on which they are registered. Patients undergo bone marrow or blood sample collection periodically for conventional cytogenetic analysis and fluorescence in situ hybridization studies (FISH). Samples are analyzed for deleted 13q/monosomy 13 and chromosomal abnormalities. PROJECTED ACCRUAL: A total of 500 patients will be accrued for this study.

Official Title
-----------------
Cytogenetic and Fluorescence In Situ Hybridization Studies in Multiple Myeloma

Conditions
-----------------
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous/Nonmalignant Condition

Intervention / Treatment
-----------------
* Genetic: cytogenetic analysis
* Genetic: fluorescence in situ hybridization


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Diagnosis of 1 of the following: Multiple myeloma (MM) Smoldering myeloma Waldenstrom's macroglobulinemia (WM) Monoclonal gammopathy of undetermined significance (MGUS) Amyloidosis (AL) Newly diagnosed disease Must be currently registered, but have not begun therapy, on 1 of the following Southwest Oncology Group (SWOG) treatment clinical trials: SWOG-S0115 SWOG-S0232 SWOG-S0340 All new SWOG coordinated MM, smoldering myeloma, WM, MGUS, or AL clinical trials activated on or after the activation date of this research study (SWOG-S0334) PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: See Disease Characteristics
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: cytogenetic analysis|marrow and peripheral blood|
|Genetic: fluorescence in situ hybridization|marrow and peripheral blood|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of deletion 13 as detected by fluorescence in situ hybridization (FISH) and conventional cytogenetics |  | 1 year | 
| Prognostic value of specific subsets of chromosome aberrations detected by conventional cytogenetics and FISH in relation to event-free and overall survival |  | 1 year | 
| Comparison of prognostic value of cytogenetics and FISH with other multiple myeloma and monoclonal gammopathy prognostic factors |  | 1 year | 
| Correlation between the presence of cytogenetic and FISH features and clinical pathophysiological, cellular, or other molecular characteristics |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Waldenstrom macroglobulinemia, monoclonal gammopathy of undetermined significance, primary systemic amyloidosis, stage I multiple myeloma, stage II multiple myeloma, stage III multiple myeloma